Outcomes in UK ACS Patients Prescribed Ticagrelor

AstraZeneca1,650 enrolled

Overview

Cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015, following ACS. Patient baseline characteristics will be described: (Age, Gender, Body Mass Index, Smoking status, Sociodemographic status), type of ACS and interventions, CV history and comorbidities, bleeding and respiratory history. The following outcomes will be examined: Incidence of vascular events (composite MI, Stroke, vascular death, specific vascular event and all cause death), incidence of bleeding and incidence of dysponea. Time to event for vascular events, bleeding and dyspnoea.

Study Type

OBSERVATIONAL

Enrollment

1,650

Conditions

Acute Coronary Syndrome

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * First prescription (index date) for ticagrelor between Dec 2010 and Mar 2015 * At least 12 months history in database prior to first ticagrelor prescription * Linkage to Hospital Episode Statistics (HES) * Acute Coronary Syndrome (ACS) event in the three months prior to and including the index date Exclusion Criteria: Primary care prescription for clopidogrel or prasugrel between the ACS date and the index date

Locations (1)

Unnamed facility

Luton, United Kingdom

Outcomes

Primary Outcomes

Incidence of composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)